Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Mol Cancer Ther. 2013 Nov 12;12(12):2917–2928. doi: 10.1158/1535-7163.MCT-13-0572

Figure 1. PTEN deficient endometrial carcinomas were refractory to PARP inhibition with high levels of circulating estrogen.

Figure 1

(A) Schema for in vivo generation and therapy of endometrial tumors driven by epithelial loss of PTEN in a high estrogen milieu. (B) Design for therapy with hormonal supplementation. (C) No significant difference in tumor mass was detected between Olaparib (n=8) or vehicle (n=8) treated tumors (p = 0.70). (D) Endometrioid tumors (a&d) containing crowded pankeratin positive (b&e) PTEN-null (c&f) epithelial glands with lumens were observed in both vehicle and Olaparib treated group. Scale bars equal 5 mm in A&C and 100 μm in D.